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What is your topic? 
Malignant Hyperthermia- Malignant 
hyperthermia is a rare, life-threatening 
disorder triggered by the use of volatile 
anesthetics agents such as succinylcholine 
(Yang et al., 2020) 
The picture above describes the 
step by step management for a 
patient with MH based on the 
MHAUS guidelines (Normandin 
& Benotti, 2018) 
Why Malignant 
Hyperthermia? 
-Malignant hyperthermia is estimated to 
occur in between 1:10,000 and 1:150,000 
anesthetic cases (Hopkins et al., 2021). 
- Malignant hyperthermia is estimated to 
have a fatality rate of 9.5% (Yang et al., 
2021). 
- MH commonly occurs when an 
individual is having their initial contact 





- Malignant Hyperthermia is due to 
an uncontrolled amount of 
calcium released from the 
sarcoplasmic reticulum into the 
myoplasm (Ravaei et al., 2020). 
The uncontrolled release of 
calcium can be due to potent 
inhalation agent, a stressor such 
as heat and exercise, 
succinylcholine (muscle relaxant), 
or a genetic mutation to the 
ryanodine receptor (Ravaei et al., 
2020). 
- The Ryanoidne receptors(RyR1) 
function to regulate the amount of 
calcium being released into the 
sarcoplasmic reticulum. When 
there is a genetic mutation in 
RyR1 an excessive amount of 
calcium is released (Chen et al., 
2017). The large amount of 
intracellular calcium leads to the 
myocyte reaching threshold 
quicker and maintain a contractile 
state for a prolonged period. 
Prolonged muscle contraction 
leads to muscle rigidity which is 
detrimental to an individual. 
Muscle rigidity increases carbon 
dioxide production, body 
temperature, oxygen requirements 
and exhaust ATP stores (Yang et 
al., 2020) 
Signs and Symptoms 
• A patient Malignant hyperthermia 
presents with multiple signs and 
symptoms 
• Hyperthermia, excessive sweating, 
mottled skin (Mayo Clinic, 2021). 
• Muscle Rigidity, excessive bleeding, 
tachycardia, masseter spasm (Cornelius et 
al., 2020) 
• Abnormal Laboratory findings include 
elevated myoglobin, calcium, potassium, 
creatine phosphokinase and serum 
myoglobin. (Sinha et al., 2017) 
The picture above displays 
all the clinical symptoms of 
MH and the percent of 
patients who present with 
that specific symptom 
(Yang et al., 2020) 
Nursing Care and Management 
- Treatment of MH includes two steps 
- Step 1: Immediate treatment 
- Step 1 involves stopping all triggering agents. If 
possible, the surgery she be stopped, if this is not 
possible then the procedure continue with the use of 
non-triggering anesthetics. 
- Call for help and administer IV Dantrolene 2.5 mg/kg 
rapidly (Cornelius et al., 2020) 
- Step 2: The second step involves symptomatic treatment. 
Hyperkalemia should be treated with calcium chloride, calcium 
gluconate or sodium bicarbonate (Yang, 2020). Hyperthermia is treated 
with administration of 2,000 ml of cold crystalloid fluids (4 degrees 
Celsius), if possible, the patient’s body should be packed with ice 
packs or cooling pads 
- Step 2: The second step involves symptomatic 
treatment. Hyperkalemia should be treated with calcium 
chloride, calcium gluconate or sodium bicarbonate 
(Yang, 2020). Hyperthermia is treated with 
administration of 2,000 ml of cold crystalloid fluids (4 
degrees Celsius), if possible, the patient’s body should 
be packed with ice packs or cooling pads 
The picture above describes the treatment process for MH (Yang et al., 2020) 
Conclusion and 
Implications 
- Maligngnat Hyperthermia is a rare 
disorder that can turn fatal if not 
recognized in a timely manner by a 
provider (Cornelius et al., 2020) 
-There are currently only two diagnostic 
methods used for MH, more research is 
needed to expand diagnostic methods and 
validity (Yang, 2020) 
- Anesthetic education on malignant 
hyperthermia should center around skills 
that will better prepare the anesthetist to 
provide adequate care to a patient 
experienced MH (Kleidon, 2020). 
- Dantrolene is currently the only acute 
treatment for MH; the use of dantrolene is 
a poor long treatment as it can lead to 
kidney and liver toxicity. 
Significance of 
Pathophysiology 
- Due to the severity of MH it is pertinent that 
health care providers recognize the initial 
signs and symptoms and treat the patient 
appropriately (Miyazaki et al., 2021). 
- If not recognized immediately a patient can 
develop irreversible kidney, liver and brain 
damage. 
Case Study 
- Case study outlines a 24-year 
old male who presented to the 
Ohio State University to receive 
dental treatment (Cornelius et 
al., 2020) 
- Pt received 200mg of 
Succinylcholine, 150 mg of 
propofol and 2% sevoflurane 
- 15 minutes into the patients 
arrival his heart rate increased 
from 82 to 123 bpm and his 
temperature increased to 38.9 
(was 35. initially). 
- Clinicians noted the patients and 
diagnosed the patient with MH 
- Help was called in and 
interventions such as 
administration of dantrolene, 
placement of ice packs around 
the individuals groin, axilla, 
neck and chest area. 
- Paramedics were called and the 
patient was transferred to the 
emergency department and 
eventually spent 4 days in the 
intensive care department. 
- 3 days later the patient was 
discharged from the hospital and 
made a complete recovery. 
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